Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Absci Corp (NQ: ABSI )

3.920 +0.080 (+2.08%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Absci Corp

< Previous 1 2 3 Next >
Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI
Collaboration brings together Absci’s Generative AI drug creation platform with Twist’s DNA synthesis platform to accelerate the design of a novel therapeutic antibody 
From Absci Corporation
Via GlobeNewswire
Absci to Participate in Upcoming Investor Conferences
From Absci Corporation
Via GlobeNewswire
Absci to Report Business Updates and Third Quarter 2024 Financial and Operating Results on November 12, 2024
From Absci Corporation
Via GlobeNewswire
Absci to Participate in Upcoming Investor Conferences
From Absci Corporation
Via GlobeNewswire
Absci Reports Business Updates and Second Quarter 2024 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
Absci Collaborates with Global Cancer Center to Discover Novel Therapeutics Using Generative AI
The collaboration unites Absci’s Generative AI Drug Creation Platform with leading oncology experts to co-develop up to six novel cancer therapeutics 
From Absci Corporation
Via GlobeNewswire
Absci to Report Business Updates and Second Quarter 2024 Financial and Operating Results on August 14, 2024
From Absci Corporation
Via GlobeNewswire
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Absci Corporation
Via GlobeNewswire
Absci to Participate in the Morgan Stanley 3rd Annual Life Sciences AI Summit
From Absci Corporation
Via GlobeNewswire
Absci to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Absci Corporation
Via GlobeNewswire
Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
Absci to Report Business Updates and First Quarter 2024 Financial and Operating Results on May 14, 2024
From Absci Corporation
Via GlobeNewswire
Absci to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Absci Corporation
Via GlobeNewswire
Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Absci Corporation
Via GlobeNewswire
Absci Announces Pricing of Public Offering of Common Stock
From Absci Corporation
Via GlobeNewswire
Absci Announces Proposed Public Offering of Common Stock
From Absci Corporation
Via GlobeNewswire
Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI
IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after 
From Absci Corporation
Via GlobeNewswire
Absci to Participate in Upcoming Investor Conferences
From Absci Corporation
Via GlobeNewswire
Absci Appoints Professor Sir Mene Pangalos to its Board of Directors
From Absci Corporation
Via GlobeNewswire
Absci to Present Preclinical Data for ABS-101, A Potential Best-in-Class Anti-TL1A Antibody Development Program, at 42nd Annual J.P. Morgan Healthcare Conference
From Absci Corporation
Via GlobeNewswire
Absci to Participate in the 26th Annual Needham Growth Conference
From Absci Corporation
Via GlobeNewswire
Absci to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Absci Corporation
Via GlobeNewswire
Absci and PrecisionLife Announce Strategic R&D Partnership to Jointly Develop AI-Enabled Drug Pipeline
From Absci Corporation
Via GlobeNewswire
Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate
Collaboration Combines Absci’s AI Antibody Drug Creation Platform with AstraZeneca’s Expertise in Oncology Research and Development 
From Absci Corporation
Via GlobeNewswire
Absci to Participate in the Piper Sandler 35th Annual Healthcare Conference
From Absci Corporation
Via GlobeNewswire
Absci Reports Business Updates and Third Quarter 2023 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases
From Almirall S.A.
Via Business Wire
Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases
The collaboration expands Absci’s de novo AI drug creation portfolio into dermatology and accelerates discovery for broader chronic inflammatory diseases 
From Absci Corporation
Via GlobeNewswire
Absci to Participate in Upcoming Investor Conferences
From Absci Corporation
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.